lymphoblastic leukaemia with t(13;13)(q12;q22) involving FLT3. 
There is no single accepted treatment approach for mantle cell lymphoma (MCL). Currently, as a general paradigm, young, fit patients receive intensive therapy, usually with high dose chemotherapy and autologous stem cell support consolidation. The more prevalent older or less fit patient often receives less intensive therapy (reviewed in Spurgeon et al.
1
). R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) has remained a commonly used initial therapy for MCL, yielding high response rates but with limited durability, 2 and still serves as a comparator in recently published studies. [3] [4] [5] The treatment landscape for MCL when E1499 was designed in the early 2000s often included R-CHOP for six cycles, with consolidative autologous stem cell support in a selected subset of patients, followed by observation. Maintenance rituximab was not generally applied. Given that relatively few MCL patients actually proceed to autologous stem cell support, ECOG-ACRIN designed its earlier trials in MCL to encompass the general MCL population.
The phase 2 E1499 trial, the first MCL trial performed by ECOG-ACRIN, was designed to test the hypothesis that a single dose of radioimmunotherapy (RIT) consolidation with 90 Y-ibritumomab tiuxetan after only four cycles of R-CHOP as initial therapy for MCL would be safe, well tolerated and improve time-to-treatment failure (TTF) compared with historical R-CHOP data. E1499 met its primary end point with TTF at 1.5 years of 69% (95% confidence interval: 58-78%) 6 and treatment was well tolerated. Here we report 10-year follow-up data on this uniformly treated cohort of patients with MCL.
As we previously reported, 6 56 eligible patients with previously untreated MCL and adequate organ function were enrolled between November 2003 and February 2005. Median age at enrollment was 60 (range 33-83) years, 73% were male and mantle cell lymphoma international prognostic index (MIPI) was low in 50%, intermediate in 27% and high in 21%. Pathology material for all cases was centrally reviewed. Therapy consisted of standard dose R-CHOP given every 3 weeks for only four cycles. Patients were re-staged with CT imaging 3-4 weeks after the fourth cycle was administered. Those whose disease had not progressed proceeded to receive a standard administration of 90 Y-ibritumomab tiuxetan. 7 Per the approved methodology, 0.4 mCi/kg (maximum 32 mCi) was infused, preceded by rituximab 250 mg/m 2 1 week before, and again on the day of, RIT. All planned therapy was administered to 51 patients (91%). The reason for not receiving RIT in five patients was disease progression in three, one inter-current death from myocardial infarction and one patient preference.
Median follow-up is now 9.8 years (May 2015 data cutoff). Response rates and duration are similar to previously reported values. The overall objective response rate after all treatment was 82% (55% complete remission CR/CRu). Median TTF is 34 months, compared with the historical target of 18 months.
2 By MIPI scores, TTF was 36 months for low (n = 28), 25 months for intermediate (n = 15) and 10 months for high MIPI (n = 12). For patients who achieved CR, median TTF was 37 months vs 14 months for all other patients (P = 0.01). Median overall survival (OS) for the entire cohort of 56 eligible patients is 7.9 years. For those under 65 years of age at entry on study, median OS has not been reached at 10 years, compared with 5.7 years for those 65 years or older (P = 0.07; Figure 1 ). OS for patients with low MIPI scores also has not been reached at 10 years, is 8.2 years for intermediate MIPI and 5.5 years for those with high baseline MIPI. Although TTF was longer for patients who achieved CR/CRu, OS did not differ significantly (P = 0.19).
No unexpected short-or long-term toxicity has been reported. In contrast, RIT consolidation after more intense induction was Accepted article preview online 26 October 2016; advance online publication, 11 November 2016 reportedly more toxic. 8 Although extensive long-term toxicity monitoring has not been carried out in our study, all second malignancies are captured. There has been no additional therapyrelated myeloid neoplasia other than the one previously reported which occurred subsequent to additional therapy. Other reported malignancies include non-small cell lung cancer (N = 2), bladder cancer (N = 1), ampullary adenocarcinoma (N = 1) and resected localized non-melanoma skin cancers (N = 2). 
Letters to the Editor
Long-term follow-up of this cohort of patients treated with a simple 4-month outpatient regimen continues to suggest a benefit for RIT consolidation in prolonging TTF, with median TTF of almost 3 years, compared with a full course of R-CHOP without maintenance as reported in other studies having TTF or PFS of o2 years. Specifically, though in somewhat older populations, in the LYM-3002 trial 4 median PFS was 14 months for six cycles of R-CHOP alone (compared with 25 months for six cycles of VR-CAP), and 22 months for six cycles of R-CHOP in the StiL trial. 3 Ongoing rituximab maintenance after eight cycles of R-CHOP is another effective consolidation strategy with 57% of patients progressionfree at 4 years. 5 RIT may be viewed as an alternative to maintenance rituximab following induction therapy, but testing this hypothesis may not be of high priority with newer agents available.
Overall survival (OS) is an important end point in an incurable disease such as MCL. Median OS for our entire cohort is 7.9 years. For OS, age was the single most important prognostic factor in this cohort. MIPI was also important. Patients with high MIPI had short TTF, however, their OS suggests that additional therapies were effective even in this high risk group. We do not have uniformly assessed Ki67 data for evaluation. As novel agents rapidly move into first-line regimens, often based on early assessments of efficacy based on response rates and duration, 9 but not OS, these long-term data will inform benchmark expectations of OS in MCL.
As MIPI is highly dependent on age, most younger patients have low or intermediate MIPI. Thus, as expected, patients under age 65 in our trial (N = 35), who today would generally be considered for intensive treatment approaches, commonly had low or intermediate MIPI (N = 30 of 35). Specifically examining this subset of patients, that is age ⩽ 65 years with low or intermediate MIPI, median OS has not been reached at 10 years. OS in these young patients treated in our study with a short course of simple outpatient therapy is comparable to contemporaneous studies using intense initial therapy [10] [11] [12] [13] [14] [15] (Table 1 ). This indicates the need for cautious interpretation of apparent prolonged OS in uncontrolled trials with various regimens as patient selection, in particular age and MIPI score, play an important role.
We conclude, with 10-year follow-up for OS of this uniformly treated cohort, that a brief, o 4-month therapeutic regimen consisting of R-CHOP for four cycles followed by one administration of 90 Y-RIT is an active regimen for initial treatment of MCL.
